Narayan RR, et al. - In resected colorectal cancer (CRC) patients, researchers examined the utility of circulating tumor DNA (ctDNA) in predicting disease outcome. They prospectively enrolled 60 patients with CRC in this prospective pilot study. Blood was drawn from peripheral (PERIPH), portal (PV), and hepatic (HV) veins during liver resection, and 3-4 weeks postoperatively from a peripheral vein (POSTOP). The most commonly mutated genes were TP53 (mtTP53: 47.5%) and APC (mtAPC: 50.8%) for the 59 eligible patients. ctDNA from PERIPH and PV, and HV, showed substantial to a nearly perfect agreement. Fair-to-moderate agreement was reported between tumor mutations and PERIPH ctDNA. They identified worse 2-year disease-specific survival in correlation to the detection of PERIPH mtTP53.